{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:48:19Z","timestamp":1782287299114,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,24]]},"DOI":"10.7759\/cureus.111402","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:14:58Z","timestamp":1782285298000},"source":"Crossref","is-referenced-by-count":0,"title":["Synchronous HER2-Positive Breast and Gastric Cancers: A Dual Diagnostic Challenge With a Single Treatment Possibility"],"prefix":"10.7759","author":[{"given":"Jeremi","family":"Morka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Biernat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Czerwinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaudia","family":"Cybulska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmara","family":"Cybulska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Rysak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Sobczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Mr\u00f3z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12081940","article-title":"Synchronous\/metachronous multiple primary malignancies: review of associated risk factors","volume":"12","author":"Pan SY","year":"2022","unstructured":"Pan SY, Huang CP, Chen WC. Synchronous\/metachronous multiple primary malignancies: review of associated risk factors. Diagnostics (Basel). 2022, 12:1940. 10.3390\/diagnostics12081940","journal-title":"Diagnostics (Basel)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08766-9","article-title":"Risks and cancer associations of metachronous and synchronous multiple primary cancers: a 25-year retrospective study","volume":"21","author":"Tanjak P","year":"2021","unstructured":"Tanjak P, Suktitipat B, Vorasan N, et al.. Risks and cancer associations of metachronous and synchronous multiple primary cancers: a 25-year retrospective study. BMC Cancer. 2021, 21:1045. 10.1186\/s12885-021-08766-9","journal-title":"BMC Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000172","article-title":"Multiple primary tumours: challenges and approaches, a review","volume":"2","author":"Vogt A","year":"2017","unstructured":"Vogt A, Schmid S, Heinimann K, Frick H, Herrmann C, Cerny T, Omlin A. Multiple primary tumours: challenges and approaches, a review. ESMO Open. 2017, 2:e000172. 10.1136\/esmoopen-2017-000172","journal-title":"ESMO Open"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/250727","article-title":"Synchronous and metachronous breast malignancies: a cross-sectional retrospective study and review of the literature","volume":"2014","author":"Londero AP","year":"2014","unstructured":"Londero AP, Bernardi S, Bertozzi S, et al.. Synchronous and metachronous breast malignancies: a cross-sectional retrospective study and review of the literature. Biomed Res Int. 2014, 2014:250727. 10.1155\/2014\/250727","journal-title":"Biomed Res Int"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref6","unstructured":"National Cancer Institute. SEER. Cancer stat facts. female breast cancer subtypes. (2024). Accessed: September 14, 2025: https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2020_200130N96","article-title":"Comparison of the efficacy and safety of the EC-T (epirubicin\/cyclophosphamide followed by docetaxel) and TCb (docetaxel\/carboplatin) neoadjuvant regimens in early TOP2A-normal stage II-III breast cancer","volume":"67","author":"Li WP","year":"2020","unstructured":"Li WP, Zhu T, Hu MX, et al.. Comparison of the efficacy and safety of the EC-T (epirubicin\/cyclophosphamide followed by docetaxel) and TCb (docetaxel\/carboplatin) neoadjuvant regimens in early TOP2A-normal stage II-III breast cancer. Neoplasma. 2020, 67:1409-15. 10.4149\/neo_2020_200130N96","journal-title":"Neoplasma"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-0430","article-title":"HER2 amplification in tumors activates PI3K\/AKT signaling independent of HER3","volume":"78","author":"Ruiz-Saenz A","year":"2018","unstructured":"Ruiz-Saenz A, Dreyer C, Campbell MR, Steri V, Gulizia N, Moasser MM. HER2 amplification in tumors activates PI3K\/AKT signaling independent of HER3. Cancer Res. 2018, 78:3645-58. 10.1158\/0008-5472.CAN-18-0430","journal-title":"Cancer Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3181-0","article-title":"Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells","volume":"17","author":"Huang Y","year":"2017","unstructured":"Huang Y, Burns DJ, Rich BE, et al.. Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells. BMC Cancer. 2017, 17:199. 10.1186\/s12885-017-3181-0","journal-title":"BMC Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.123087","article-title":"HER3: updates and current biology function, targeted therapy and pathologic detecting methods","volume":"357","author":"Gao L","year":"2024","unstructured":"Gao L, Zhang Y, Feng M, et al.. HER3: updates and current biology function, targeted therapy and pathologic detecting methods. Life Sci. 2024, 357:123087. 10.1016\/j.lfs.2024.123087","journal-title":"Life Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-017-1132-5","article-title":"The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature","volume":"15","author":"Lei YY","year":"2017","unstructured":"Lei YY, Huang JY, Zhao QR, et al.. The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature. World J Surg Oncol. 2017, 15:68. 10.1186\/s12957-017-1132-5","journal-title":"World J Surg Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-05772-6","article-title":"Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer","volume":"183","author":"Stocker A","year":"2020","unstructured":"Stocker A, Trojan A, Elfgen C, Hilbers ML, Moskovszky L, Varga Z. Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer. Breast Cancer Res Treat. 2020, 183:311-9. 10.1007\/s10549-020-05772-6","journal-title":"Breast Cancer Res Treat"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101404","article-title":"The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: a population-based modelling study","volume":"47","author":"Morgan E","year":"2022","unstructured":"Morgan E, Arnold M, Camargo MC, et al.. The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: a population-based modelling study. EClinicalMedicine. 2022, 47:101404. 10.1016\/j.eclinm.2022.101404","journal-title":"EClinicalMedicine"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn169","article-title":"HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target","volume":"19","author":"Gravalos C","year":"2008","unstructured":"Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008, 19:1523-9. 10.1093\/annonc\/mdn169","journal-title":"Ann Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1515\/pterid-2017-0017","article-title":"Neoadjuvant combination therapy with trastuzumab in a breast cancer patient with synchronous rectal carcinoma: a case report and biomarker study","volume":"28","author":"Vit\u00e1skov\u00e1 D","year":"2017","unstructured":"Vit\u00e1skov\u00e1 D, Melichar B, Bartou\u0161kov\u00e1 M, et al.. Neoadjuvant combination therapy with trastuzumab in a breast cancer patient with synchronous rectal carcinoma: a case report and biomarker study. Pteridines. 2017, 28:233-41. 10.1515\/pterid-2017-0017","journal-title":"Pteridines"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-23-0302","article-title":"HER2-selective and reversible tyrosine kinase inhibitor tucatinib potentiates the activity of T-DM1 in preclinical models of HER2-positive breast cancer","volume":"3","author":"Olson D","year":"2023","unstructured":"Olson D, Taylor J, Willis K, et al.. HER2-selective and reversible tyrosine kinase inhibitor tucatinib potentiates the activity of T-DM1 in preclinical models of HER2-positive breast cancer. Cancer Res Commun. 2023, 3:1927-39. 10.1158\/2767-9764.CRC-23-0302","journal-title":"Cancer Res Commun"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112978","article-title":"Genome-guided discovery of cancer therapeutic targets","volume":"42","author":"Konda P","year":"2023","unstructured":"Konda P, Garinet S, Van Allen EM, Viswanathan SR. Genome-guided discovery of cancer therapeutic targets. Cell Rep. 2023, 42:112978. 10.1016\/j.celrep.2023.112978","journal-title":"Cell Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4048\/jbc.2015.18.2.167","article-title":"Treatment outcome of breast cancer with pathologically proven synchronous ipsilateral supraclavicular lymph node metastases","volume":"18","author":"Jung J","year":"2015","unstructured":"Jung J, Kim SS, Ahn SD, et al.. Treatment outcome of breast cancer with pathologically proven synchronous ipsilateral supraclavicular lymph node metastases. J Breast Cancer. 2015, 18:167-72. 10.4048\/jbc.2015.18.2.167","journal-title":"J Breast Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30026-9","article-title":"Immunotherapy and targeted therapy combinations in metastatic breast cancer","volume":"20","author":"Esteva FJ","year":"2019","unstructured":"Esteva FJ, Hubbard-Lucey VM, Tang J, Pusztai L. Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol. 2019, 20:e175-86. 10.1016\/S1470-2045(19)30026-9","journal-title":"Lancet Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.mpsur.2023.12.004","article-title":"Targeted therapies in cancer","volume":"42","author":"Sylva RM","year":"2024","unstructured":"Sylva RM, Ahmed SI. Targeted therapies in cancer. Surgery (Oxford). 2024, 42:150-5. 10.1016\/j.mpsur.2023.12.004","journal-title":"Surgery (Oxford)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/502279-synchronous-her2-positive-breast-and-gastric-cancers-a-dual-diagnostic-challenge-with-a-single-treatment-possibility","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:15:06Z","timestamp":1782285306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/502279-synchronous-her2-positive-breast-and-gastric-cancers-a-dual-diagnostic-challenge-with-a-single-treatment-possibility"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.111402","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,24]]}}}